July 13, 2016 The consequences of stigma among people living with and vulnerable to HIV infection are significant and far-reaching. Stigma is frequently cited as a significant barrier to successful pre-exposure prophylaxis (PrEP) awareness, access and utilization. Despite having been…
A conference call meeting initiated by HIV community advocates was held with FDA members on June 10, 2016 to discuss ways to advance the evaluation and development of products (drugs or biologics) that demonstrate promise in improving health outcomes in HIV-positive patients with inadequate immune response after long term successful HIV treatment.
Dear Senator Sanders: We are grateful that you took time to sit with us this week to discuss a broad range of issues related to the fight against HIV/AIDS. Our group represents a larger coalition of over 70 organizations and advocates from across the country who hope to use this opportunity to push forward the national conversation, which is sorely missing, about HIV/AIDS. While we were optimistic following what we felt was a productive meeting, our optimism quickly turned to disappointment when your campaign issued a news release misrepresenting the meeting with HIV/AIDS leadership entitled “Sanders Backs California Ballot Initiative to Rein in Drug Prices at Meeting with HIV/AIDS Advocates.”
April 2016 The Daily Telegraph article and examples of the media coverage that followed it: Cure for HIV possible within three years as scientists snip virus from cells– The Daily Telegraph, April 1, 2016. Update April 6, 2016: After receiving complaints, The Daily…
Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability By Tracy Swan TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work…
A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them By James Krellenstein and Jeremiah Johnson On July 16, 2012, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’…
Dear Secretary Clinton: We write to you in the sincere hope that we can work together to transform the pain caused by your March 11th mischaracterization of the Reagans’ role in the AIDS crisis into an urgently needed public discussion of a plan to end the United States HIV epidemic by the year 2025.
Secretary Clinton's mischaracterization of the Reagan Administration on Friday, March 11, sparked nationwide upset from HIV/AIDS advocates, service providers, people living with HIV, and loved ones of those lost to the epidemic. But it also has created an opportunity to bring HIV/AIDS to the forefront of the conversation during this campaign season.
On Sunday February 21, 2016 in Boston, the AIDS Treatment Activists Coalition, AVAC, European AIDS Treatment Group, Project Inform and TAG co-sponsored a community workshop on HIV cure research. The workshop has become an annual event that takes place immediately…
"Governor Cuomo continues to provide globally unprecedented leadership with New York State's plan to end AIDS as an epidemic by the year 2020,” said Treatment Action Group executive director Mark Harrington.